Meloxicam Tablet
Product Images NDC 72789-403

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 72789-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789402)

Label for Meloxicam Tablets, USP 7.5 mg by PD-Rx Pharmaceuticals, Inc. The label shows 90 tablets in the package, with storage instructions and a warning to keep medications out of children's reach. It includes NDC 72789-402-90, expiration date 10/2024, and a barcode for scanning.*

FDA Label Image

Image (72789403)

Label for Meloxicam Tablets, USP 15 mg, oral tablets by PD-Rx Pharmaceuticals, Inc. The label states the quantity as 90 tablets and includes storage instructions, pharmacist dispensing guidance, barcode, and manufacturing details from Oklahoma City, OK.*

FDA Label Image

Mg1 (Mg1)

A text panel discussing precautions related to the use of NSAIDs, including warnings against taking NSAIDs right before or after coronary artery bypass graft (CABG) surgery and after a recent heart attack, highlighting increased risk of another heart attack in such cases.*

FDA Label Image

Mg2 (Mg2)

A partial text panel from a medication guide or prescribing information discussing risk factors for ulcer or bleeding related to NSAID use. It lists conditions and factors increasing risk such as past stomach ulcers, use of corticosteroids, anticoagulants, SSRIs, SNRIs, older age, smoking, alcohol use, advanced liver disease, and bleeding problems.*

FDA Label Image

Mg3 (Mg3)

A partial text panel containing medication instructions or warnings related to Meloxicam tablets. The visible text mentions adherence to prescribed doses, minimizing treatment dosage, and limiting treatment duration. The full drug facts or prescribing information is not visible.*

FDA Label Image

Mg4 (Mg4)

This image shows a Drug Facts panel containing warnings and serious side effects for a medication, including symptoms such as shortness of breath, chest pain, weakness in one part or side of the body, slurred speech, and swelling of the face or throat. The text is presented as bullet points.*

FDA Label Image

Mg5 (Mg5)

A partial text panel listing possible side effects and symptoms to watch for with use of Meloxicam tablets. The visible content includes symptoms such as nausea, diarrhea, itching, yellowing of skin or eyes, vomiting blood, unusual weight gain, and swelling of limbs, among others, presented in bullet points.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of Meloxicam, depicting the molecular arrangement of its atoms and bonds, including sulfur and nitrogen heterocycles, consistent with the nonproprietary drug Meloxicam used in the product MELOXICAM by PD-Rx Pharmaceuticals, Inc.*

FDA Label Image

Table 1a (Table 1a)

A data table titled 'Table 1a Adverse Events (%) Occurring in ≥2% of Meloxicam Patients in a 12-Week Osteoarthritis Placebo- and Active-Controlled Trial.' It compares adverse events percentages for Placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily across categories including Gastrointestinal, Body as a Whole, Central and Peripheral Nervous System, Respiratory, and Skin.*

FDA Label Image

Table 1b (Table 1b)

A data table showing adverse events occurring in 2% or more of Meloxicam patients during two 12-week rheumatoid arthritis placebo-controlled trials. The table compares percentage rates for Placebo, Meloxicam 7.5 mg daily, and Meloxicam 15 mg daily across categories including gastrointestinal disorders, general disorders and administration site conditions, infections, musculoskeletal disorders, nervous system disorders, and skin and subcutaneous tissue disorders.*

FDA Label Image

Table 2.1 (Table 2.1)

A table listing adverse reactions and side effects associated with Meloxicam, organized by body systems such as cardiovascular, gastrointestinal, hepatic, respiratory, psychiatric, urinary, and others. The table details specific symptoms or conditions under each system relevant to the medication's safety profile.*

FDA Label Image

Table 2 (Table 2)

A table presenting adverse events occurring in 2% or more of patients treated with Meloxicam 7.5 mg and 15 mg daily in 4 to 6 weeks and 6 month active-controlled osteoarthritis trials. The table categorizes adverse events by system organ class such as gastrointestinal, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary, with associated percentages of occurrences in patient groups.*

FDA Label Image

Table 3.1 (Table 3.1)

A text panel detailing drug interaction information for meloxicam tablets. It summarizes clinical impacts and recommended interventions when meloxicam is used concomitantly with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed. The panel provides specific guidance for monitoring and dosing adjustments related to renal function and toxicity risks.*

FDA Label Image

Table 3 (Table 3)

Table titled "Clinically Significant Drug Interactions with Meloxicam" listing several categories of drugs including anticoagulants, aspirin, ACE inhibitors, beta-blockers, and diuretics. Each category details their clinical impact and recommended interventions or monitoring when used concomitantly with meloxicam.*

FDA Label Image

Image Description (Table 4)

A table presenting single dose and steady-state pharmacokinetic parameters for oral meloxicam at 7.5 mg and 15 mg strengths. It includes data on healthy male adults, elderly males and females, and patients with renal failure or hepatic insufficiency, covering metrics such as Cmax, tmax, t1/2, CL/f, and Vz/f with variability percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.